Interim report Q3 2024
Business Highlights during and after the third quarter of 2024 · Curasight designates brain cancer as initial indication for uTREAT · Clinical Phase II trial of uPAR-PET in brain cancer patients · Strong demand for rights issue resulted in heavy oversubscription · Continued business development activities with industry players Copenhagen, Denmark, 21 November 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the third quarter, and the first nine months, 2024. The interim report is available as an attached file to this